当前疫苗接种建议之外的严重侵袭性肺炎球菌病:对高价结合疫苗的启示
该回顾性研究纳入2019年1月至2024年12月瑞士南部四家医院210例微生物学确诊的成人侵袭性肺炎球菌病(IPD)患者,描述其流行病学、临床特征与血清型分布,并计算PCV13、PCV15、PCV20、PCV21的理论覆盖率。结果显示37.6%入住ICU、8.6%死亡,Charlson合并症指数是ICU入住(OR 1.25,95%CI 1.02-1.57)和死亡(OR 2.37,95%CI 1.54-3.64)的唯一独立预测因子;血清型8最常见(21.0%),其次为3型(13.3%)和4型(9.5%);仅9.9%既往接种过肺炎球菌疫苗。26.7%的患者年龄<65岁且无合并症、无接种指征,其中44.6%入住ICU,该亚组血清型8占30.4%。在无接种指征成人中,PCV13和PCV15理论覆盖28.6%和33.9%,而PCV20和PCV21覆盖67.9%和73.2%。
要点
- 210例成人IPD中37.6%入住ICU、8.6%死亡;Charlson合并症指数是ICU入住(OR 1.25,95%CI 1.02-1.57)和死亡(OR 2.37,95%CI 1.54-3.64)的唯一独立预测因子。
- 26.7%(56例)患者年龄<65岁且无合并症、无现行接种指征,其中44.6%入住ICU,该亚组血清型8占30.4%。
- 血清型8为最常见分离株(21.0%),其次为3型(13.3%)和4型(9.5%);仅9.9%患者既往接种过肺炎球菌疫苗。
- 无接种指征成人中,PCV13和PCV15理论覆盖28.6%和33.9%,PCV20和PCV21覆盖67.9%和73.2%。
适用人群与场景
- 2019年1月至2024年12月瑞士南部四家医院收治的、微生物学确诊的成人侵袭性肺炎球菌病患者,共210例,平均年龄69.3岁。
研究设计与关键结果
- 回顾性研究,纳入瑞士南部四家医院2019年1月至2024年12月210例微生物学确诊的成人IPD患者,平均年龄69.3岁;79例(37.6%)入住ICU,18例(8.6%)死亡。
- Charlson合并症指数是ICU入住的唯一独立预测因子(OR 1.25,95%CI 1.02-1.57),也是死亡的唯一独立预测因子(OR 2.37,95%CI 1.54-3.64)。
- 血清型8最常见(21.0%),其次为血清型3(13.3%)和血清型4(9.5%);仅9.9%患者既往接种过肺炎球菌疫苗。
- 56例(26.7%)患者年龄<65岁且无合并症、无疫苗接种指征,其中44.6%入住ICU,该亚组中血清型8占30.4%。
- 无接种指征成人中,PCV13理论覆盖28.6%、PCV15覆盖33.9%、PCV20覆盖67.9%、PCV21覆盖73.2%。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高价结合疫苗可显著扩大该人群的血清型覆盖,支持重新考虑基于年龄的疫苗接种策略。
- 研究提示,超过四分之一的成人IPD发生在无现行接种指征者中,且重症比例高(该亚组44.6%入住ICU)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe the epidemiology, clinical characteristics, and serotype distribution of invasive pneumococcal disease (IPD) in adults in Southern Switzerland, and to evaluate the theoretical coverage of higher-valency pneumococcal conjugate vaccines, with particular focus on patients without current vaccination indications.
METHODS: This retrospective study included all adults with microbiologically confirmed IPD admitted to four hospitals in Southern Switzerland between January 2019 and December 2024. Clinical data, serotypes, and vaccination status were collected. Theoretical vaccine coverage was calculated for PCV13, PCV15, PCV20, and PCV21. Multivariable logistic regression identified predictors of intensive care unit (ICU) admission and mortality.
RESULTS: Among 210 patients (mean age 69.3 years), 79 (37.6%) were admitted to the ICU and 18 (8.6%) died. Charlson Comorbidity Index was the only independent predictor of both ICU admission (OR 1.25, 95% CI 1.02-1.57) and mortality (OR 2.37, 95% CI 1.54-3.64). Serotype 8 was the most frequent isolate (21.0%), followed by serotypes 3 (13.3%) and 4 (9.5%). Only 9.9% of patients had received prior pneumococcal vaccination. Fifty-six patients (26.7%) were aged < 65 years without comorbidities and had no vaccination indication; 44.6% of these were admitted to the ICU. Serotype 8 accounted for 30.4% of infections in this subgroup. PCV13 and PCV15 would have covered 28.6% and 33.9% of cases in non-eligible adults, whereas PCV20 and PCV21 would have covered 67.9% and 73.2%, respectively.
CONCLUSIONS: More than one-quarter of adult IPD occurred in individuals without current vaccination indications, with high rates of severe disease. Higher-valency conjugate vaccines could substantially expand serotype coverage in this population, supporting reconsideration of age-based vaccination strategies.
参考来源
- Ramponi N, Barda B, Barilaro G, et al. Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines. Eur J Clin Microbiol Infect Dis. 2026. PMID: 42550395. doi:10.1007/s10096-026-05602-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。